Disease Clusters?
Groups of diseases that share a large number of curated genes with each other, computed via label propagation over the shared-gene similarity graph. See also Shared-Gene Disease Pairs for pairwise comparisons.
← Back to all clusters
Cluster 108
11
Diseases
19
Unique genes
0.238
Avg. similarity score
Atypical hemolytic uremic syndrome
Most-connected disease (6 links)
Disease
Searched: Doyne honeycomb retinal dystrophy
Pinned (dragged)
Node size = connections within this cluster · edge thickness = similarity strength · hover an edge for its details ·
click a node to select it and show its pairs below (double-click or Ctrl/⌘-click opens the disease page) ·
drag a node to pin it in place · scroll/pinch to zoom.
Doyne honeycomb retinal dystrophy
Atypical hemolytic uremic syndrome
Factor h deficiency
Genetic hemolytic uremic syndrome
Panuveitis
Thrombotic microangiopathy
Central serous retinopathy
Factor i deficiency
Choroid diseases
Intellectual developmental disorder seizures cerebellar
Throat disease
Member diseases (most connected first ‐ the cluster's core)
| Disease ⇵ | Connections in cluster ⇵ | Significant partners ⇵ | Curated genes ⇵ |
|---|---|---|---|
| Atypical hemolytic uremic syndrome | 6 | 6 | 3 |
| Factor h deficiency | 6 | 6 | 1 |
| Genetic hemolytic uremic syndrome | 6 | 6 | 1 |
| Panuveitis | 6 | 6 | 2 |
| Thrombotic microangiopathy | 6 | 6 | 3 |
| Central serous retinopathy | 5 | 5 | 11 |
| Doyne honeycomb retinal dystrophy | 5 | 5 | 4 |
| Factor i deficiency | 3 | 3 | 1 |
| Choroid diseases | 1 | 1 | 1 |
| Intellectual developmental disorder seizures cerebellar | 1 | 1 | 1 |
| Throat disease | 1 | 1 | 3 |
Top shared genes (genes linked to 2+ member diseases)
| Gene ⇵ | Member diseases ⇵ | Linked diseases |
|---|---|---|
| CFH | 7 / 11 | Atypical hemolytic uremic syndrome, Central serous retinopathy, Doyne honeycomb retinal dystrophy, Factor h deficiency and 3 more |
| CFI | 4 / 11 | Atypical hemolytic uremic syndrome, Doyne honeycomb retinal dystrophy, Factor i deficiency, Thrombotic microangiopathy |
| GATA5 | 2 / 11 | Central serous retinopathy, Throat disease |
| IL10 | 2 / 11 | Choroid diseases, Panuveitis |
| RORA | 2 / 11 | Central serous retinopathy, Intellectual developmental disorder seizures cerebellar |
What do these columns mean?
- Connections in cluster
- How many other members this disease has a shared-gene link to (the node size in the network above). The most-connected diseases are the cluster's core.
- Significant partners
- How many of those links are statistically significant (FDR q < 0.05).
- Curated genes
- Distinct curated genes linked to that disease in GeDiPNet.
- Member diseases (Top shared genes)
- How many of this cluster's diseases are linked to the gene, out of the cluster's total. Genes shared by many members are the most direct explanation of why they group together.
- Overlap genes (x / y)
- x = genes shared between this cluster and the pathway/GO term; y = that pathway/GO term's total gene count. A higher x relative to y (and to the cluster's own size) means a tighter biological match.
- Cluster gene count
- Total distinct genes across every disease in this cluster -- the "n" used in the significance test below.
- Fold enrichment
- Observed overlap divided by the overlap expected by chance, given the cluster's gene count, the pathway/term's size and the gene universe tested. 5× means five times more shared genes than random. Tells strong hits apart when q-values are all vanishingly small.
- P-value / FDR q-value
- Is this pathway/GO term's overlap with the cluster more than chance? Upper-tail hypergeometric test, Benjamini-Hochberg corrected across every tested pathway/term (prefer the q-value -- it accounts for testing many at once).
- Shared genes (Pairs within this cluster)
- Number of curated genes the two diseases in that row have in common.
- Similarity score (Pairs within this cluster)
- Jaccard-based gene overlap between the two specific diseases in that row -- same metric as the main Shared-Gene Disease Pairs page.
Enriched Pathways (why this cluster is grouped, biologically)
| Pathway ⇵ | Source ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| Regulation of Complement cascade | Reactome | 3 / 47 | 40.3× | 5.21e-5 | 1.34e-3 ✓ sig. |
| Complement and coagulation cascades | KEGG | 3 / 88 | 21.5× | 3.38e-4 | 5.99e-3 ✓ sig. |
| Staphylococcus aureus infection | KEGG | 3 / 99 | 19.2× | 4.78e-4 | 7.88e-3 ✓ sig. |
| Negative regulation of NOTCH4 signaling | Reactome | 1 / 2 | 316× | 3.16e-3 | 3.24e-2 ✓ sig. |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | Reactome | 1 / 2 | 316× | 3.16e-3 | 3.24e-2 ✓ sig. |
| Inflammatory bowel disease | KEGG | 2 / 66 | 19.2× | 4.79e-3 | 4.33e-2 ✓ sig. |
| Virion - Adenovirus | KEGG | 1 / 4 | 158× | 6.31e-3 | 5.22e-2 |
| STING mediated induction of host immune responses | Reactome | 1 / 5 | 126× | 7.89e-3 | 6.04e-2 |
| Defective LFNG causes SCDO3 | Reactome | 1 / 5 | 126× | 7.89e-3 | 6.04e-2 |
| Pre-NOTCH Processing in Golgi | Reactome | 1 / 6 | 105× | 9.46e-3 | 6.76e-2 |
| Interleukin-4 and Interleukin-13 signaling | Reactome | 2 / 108 | 11.7× | 1.24e-2 | 8.00e-2 |
| CD163 mediating an anti-inflammatory response | Reactome | 1 / 9 | 70.2× | 1.42e-2 | 8.63e-2 |
| Tryptophan catabolism | Reactome | 1 / 11 | 57.5× | 1.73e-2 | 9.77e-2 |
| Virion - Ebolavirus, Lyssavirus and Morbillivirus | KEGG | 1 / 12 | 52.7× | 1.88e-2 | 1.03e-1 |
| IRF3-mediated induction of type I IFN | Reactome | 1 / 13 | 48.6× | 2.04e-2 | 1.07e-1 |
Enriched GO Terms (Biological Process, a second line of biological evidence)
| GO term ⇵ | GO ID ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| regulation of complement-dependent cytotoxicity | GO:1903659 | 2 / 8 | 246× | 2.73e-5 | 1.15e-3 ✓ sig. |
| negative regulation of autophagy | GO:0010507 | 3 / 73 | 40.4× | 5.30e-5 | 1.92e-3 ✓ sig. |
| negative regulation of heterotypic cell-cell adhesion | GO:0034115 | 2 / 11 | 179× | 5.36e-5 | 1.93e-3 ✓ sig. |
| liver regeneration | GO:0097421 | 2 / 29 | 67.8× | 3.91e-4 | 8.28e-3 ✓ sig. |
| complement activation | GO:0006956 | 2 / 35 | 56.2× | 5.71e-4 | 1.07e-2 ✓ sig. |
| complement activation, classical pathway | GO:0006958 | 2 / 37 | 53.2× | 6.39e-4 | 1.15e-2 ✓ sig. |
| response to low light intensity stimulus | GO:0009645 | 1 / 1 | 984× | 1.02e-3 | 1.55e-2 ✓ sig. |
| negative regulation of chronic inflammatory response to antigenic stimulus | GO:0002875 | 1 / 1 | 984× | 1.02e-3 | 1.55e-2 ✓ sig. |
| negative regulation of cytokine activity | GO:0060302 | 1 / 1 | 984× | 1.02e-3 | 1.55e-2 ✓ sig. |
| regulation of response to wounding | GO:1903034 | 1 / 1 | 984× | 1.02e-3 | 1.55e-2 ✓ sig. |
| regulation of complement activation, alternative pathway | GO:0030451 | 1 / 1 | 984× | 1.02e-3 | 1.55e-2 ✓ sig. |
| positive regulation of L-leucine import across plasma membrane | GO:1905534 | 1 / 1 | 984× | 1.02e-3 | 1.55e-2 ✓ sig. |
| positive regulation of termination of RNA polymerase II transcription | GO:1904595 | 1 / 1 | 984× | 1.02e-3 | 1.55e-2 ✓ sig. |
| tissue development | GO:0009888 | 2 / 51 | 38.6× | 1.21e-3 | 1.74e-2 ✓ sig. |
| sequestering of extracellular ligand from receptor | GO:0035581 | 1 / 2 | 492× | 2.03e-3 | 2.34e-2 ✓ sig. |